Skip to main content
Have a personal or library account? Click to login
Regulation of p53 by siRNA in radiation treated cells: Simulation studies Cover

Regulation of p53 by siRNA in radiation treated cells: Simulation studies

Open Access
|Dec 2012

References

  1. Davis, M.E. (2009). The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic,(3): 659-668.
  2. Dorsett, Y. and Tuschl, T. (2009). siRNAs: Applications in functional genomics and potential as therapeutics,(4): 318-329.
  3. Fire, A., Xu, S., Montgomery, M., Kostas, S., Driver, S. and Mello, C. (1998). Potent and specific genetic interference by double-stranded RNA in,(6669): 806-811.
  4. Fujarewicz, K. (2010). Planning identification experiments for cell signaling pathways: An NFB case study,(4): 773-780, DOI: 10.2478/v10006-010-0059-6.
  5. García, J., Silva, J., Pen˜a, C., Garcia, V., Rodr´ıguez, R., Cruz, M.A., Cantos, B., Provencio, M., Espan˜a, P. and Bonilla, F. (2004). Promoter methylation of the PTEN gene is a common molecular change in breast cancer,(2): 117-124.
  6. Gatter, K., Brown, G., Trowbridge, I., Woolston, R. and Mason, D. (1983). Transferring receptors in human tissues: Their distribution and possible clinical relevance,(5): 539-545.
  7. Geva-Zatorsky, N., Rosenfeld, N., Itzkovitz, S., Milo, R., Sigal, A., Dekel, E., Yarnitzky, T., Liron, Y., Polak, P., Lahav, G. and Alon, U. (2006). Oscillations and variability in the p53 system,: 2006.0033.
  8. Giono, L. and Manfredi, J. (2007). Mdm2 is required for inhibition of cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest,(11): 4166-4178.
  9. Goldstein, I., Marcel, V., Olivier, M., Oren, M., Rotter, V. and Hainaut, P. (2011). Understanding wild-type and mutant p53 activities in human cancer: New landmarks on the way to targeted therapies,(1): 2-11.
  10. Hannon, G. and Rossi, J. (2004). Unlocking the potential of the human genome with RNA interference,(7006): 371-378.
  11. Harris, S. and Levine, A. (2005). The p53 pathway: Positive and negative feedback loops,(17): 2899-2908.
  12. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53,(6630): 296-299.
  13. Hrstka, R., Coates, P. and Vojtesek, B. (2009). Polymorphisms in p53 and the p53 pathway: Roles in cancer susceptibility and response to treatment,(3): 440-453.
  14. Kim, B., Tang, Q., Biswas, P., Xu, J., Schiffelers, R., Xie, F., Ansari, A., Scaria, P., Woodle, M., Lu, P. and Rouse, B. (2004). Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: Therapeutic strategy for herpetic stromal keratitis,(6): 2177-2185.
  15. Kohn, K. and Pommier, Y. (2005). Molecular interaction map of the p53 and mdm2 logic elements, which control the off-on switch of p53 in response to DNA damage,(3): 816-827.
  16. Krawczyk, B., Rudnicka, K. and Fabianowska-Majewska, K. (2007). The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in mcf-7 and mda-mb-231 breast cancer cell lines,(8-9): 1043-1046.
  17. Levine, A., Hu, W. and Feng, Z. (2006). The p53 pathway: What questions remain to be explored?,(6): 1027-1036.
  18. Li, L. and Ross, A. (2007). Why is PTEN an important tumor suppressor?,(6): 1368-1374.
  19. Li, W. and Cha, L. (2007). Predicting siRNA efficiency,(14): 1785-11792.
  20. Makinen, P., Koponen, J., Karkkainen, A., Malm, T., Pulkkinen, K., Koistinaho, J., Turunen, M. and Yla-Herttuala, S. (2006). Stable RNA interference: Comparison of u6 and h1 promoters in endothelial cells and in mouse brain,(4): 433-441.
  21. Overhoff, M., Wnsche, W. and Sczakiel, G. (2004). Quantitative detection of siRNA and single-stranded oligonucleotides: Relationship between uptake and biological activity of siRNA,(21): e170.
  22. Puszynski, K., Hat, B. and Lipniacki, T. (2008). Oscillations and bistability in the stochastic model of p53 regulation,(2): 452-465.
  23. Ryther, R., Flynt, A., Phillips, J. and Patton, J. (2005). siRNA therapeutics: Big potential from small RNAs,(1): 5-11.
  24. Shim, M. and Kwon, Y. (2010). Efficient and targeted delivery of siRNA in vivo,(23): 4814-4827.
  25. Świerniak, A., Ledzewicz, U. and Scha¨ttler, H. (2003). Optimal control for a class of compartmental models in cancer chemotherapy,(3): 357-368.
  26. Veldhoen, S., Laufer, S.D., Trampe, A. and Restle, T. (2006). Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: Quantitative analysis of uptake and biological effect,(22): 6561-6573.
DOI: https://doi.org/10.2478/v10006-012-0075-9 | Journal eISSN: 2083-8492 | Journal ISSN: 1641-876X
Language: English
Page range: 1011 - 1018
Published on: Dec 28, 2012
Published by: University of Zielona Góra
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2012 Krzysztof Puszyński, Roman Jaksik, Andrzej Świerniak, published by University of Zielona Góra
This work is licensed under the Creative Commons License.